微小RNA基因的DNA甲基化在卵巢癌中的研究

Research of DNA Methylation of MicroRNA in Ovarian Cancer

微小RNA(microRNA,miRNA)是一类短链非编码RNA,通过降解mRNA或抑制mRNA翻译的方式调控众多基因的表达。已有许多研究表明miRNA与卵巢癌的发生、发展、耐药和预后相关。DNA甲基化是表观遗传学的重要组成部分,与细胞的增殖、癌变等生命现象有着重大的关系,是目前肿瘤中研究最多的表观遗传学机制之一,与肿瘤的发生、发展、耐药和预后相关。研究卵巢癌中miRNA基因的DNA甲基化可能为卵巢癌诊治提供新的分子诊断和预后标记物,为化疗耐药分析和个性化治疗提供新的临床思路。

miRNAs（microRNAs） are a class of short non-coding RNAs that act as master regulators of gene expression through mRNA cleavage or translational repression. Recently, it has become clear that miRNA plays important roles in ovarian cancer pathogenesis, metastasis, drug resistance and prognosis. DNA methylation is an important part of epigenetics and plays important roles in tumor pathogenesis, metastasis, drug resistance and prognosis. DNA methylation is one of the most widespread research in epigenetic about tumor. The DNA methylation of miRNA in ovarian cancer may be used as a noninvasive diagnostic and prognostic biomarker in ovarian cancer, and provide a new clinical thought for the analysis of drug resistance and individualized therapy.